课题基金 / 基金详情

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
本协议的目的是国家癌症研究所(NCI)为医疗保健研究和质量局(AHRQ)的医疗支出小组调查(MEPS)提供财政支持。该项目是由NCI、疾病控制和预防中心(CDC)、美国国立卫生研究院行为和社会科学研究办公室(OBSSR)、医疗保健研究和质量局(AHRQ)、美国癌症协会(ACS)和LIVESTRONG基金会共同努力完成的。NCI和CDC之间存在单独的机构内协议。在OBSSR和NCI之间完成直接引用。为ACS和LIVESTRONG基金设立了NIH捐赠基金。
英文摘要
The purpose of this agreement is for the National Cancer Institute (NCI) to provide financial support to the Agency for Healthcare REsearch and Quality (AHRQ) for the Medical Expenditure Panel Survey (MEPS). This project is a collaborative effort between the NCI, the Centers for Disease Control and Prevention (CDC), the Office of Behavioral and Social Science Researdh (OBSSR) of the National Institutes of health, the Agency for Healthcare Research and Quality(AHRQ) , and the American Cancer Society (ACS) and the LIVESTRONG Foundation. A separate intra-agency agreement exists between the NCI and the CDC. A direct citation was completed between OBSSR and NCI. An NIH gift fund was established for ACS and LIVESTRONG funds. The Medical Expenditure Panel Survey (MEPS) is a nationally representative survey of the civilian non-institutionalized population of all ages in the United States conducted by AHRQ. The MEPS collects comprehensive data on health care and health care expenditures from all payors (including private payors, Medicaid, the VA, and out-of-pocket) over a two year period. The MEPS uses the National Health Interview Survey (NHIS) as its sample frame, but includes only a subset of the NHIS sample (about 1/4 to 1/3 of the households and individuals).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
  • 批准号:
    82505677
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.00万元
  • 批准年份:
    2025
  • 负责人:
    吕雨霏
  • 依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
  • 批准号:
    82574874
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2025
  • 负责人:
    刘天华
  • 依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位: